Progestins in HRT: sufferance or desire?

Area of Science:

• Endocrinology
• Pharmacology
• Women's Health

Background:

• Progestins are used in hormone replacement therapy (HRT) for endometrial protection.
• Controversy exists regarding progestin effects on breast tissue and cardiovascular health, highlighted by major studies like the Women's Health Initiative.
• The role of progestins in optimal post-menopausal HRT is questioned, with potential misinterpretations of epidemiological data.

Purpose of the Study:

• To critically evaluate the role and necessity of the progestin component in post-menopausal hormone therapy.
• To emphasize the diverse cellular, metabolic, and hemostatic effects of different progestins.
• To advocate for a differentiated approach to progestin selection in HRT, particularly concerning cardiovascular disease.

Main Methods:

• Review of epidemiological data and clinical studies on hormone replacement therapy.
• Analysis of the biochemical and structural differences among various progestins.
• Evaluation of tissue-specific, metabolic, and hemostatic changes induced by different progestins.

Main Results:

• Progestins exhibit varied tissue-specific effects due to structural differences.
• No single test can determine the optimal progestin for all desired hormonal effects.
• Minimizing deviations from premenopausal physiology is often advantageous.

Conclusions:

• Optimal future hormone therapy likely involves estrogen/progestin combinations.
• Selecting the right progestin requires evaluating its steroidal formula, dose titration, and route of administration.
• Differentiating between chemically and functionally distinct progestins is essential for safe and effective post-menopausal HRT, especially regarding cardiovascular health.